These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 26019801)

  • 21. Opposite role of CD44-standard and CD44-variant-3 in tubular injury and development of renal fibrosis during chronic obstructive nephropathy.
    Rampanelli E; Rouschop KM; Claessen N; Teske GJ; Pals ST; Leemans JC; Florquin S
    Kidney Int; 2014 Sep; 86(3):558-69. PubMed ID: 24717295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decreased levels of CD44 protein and mRNA in prostate carcinoma. Correlation with tumor grade and ploidy.
    Kallakury BV; Yang F; Figge J; Smith KE; Kausik SJ; Tacy NJ; Fisher HA; Kaufman R; Figge H; Ross JS
    Cancer; 1996 Oct; 78(7):1461-9. PubMed ID: 8839552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of CD44 in primary lung carcinomas using histological and cytological analyses.
    Shimbori M; Kijima H; Sato S; Yoshida H; Sato T; Terasaki-Fukuzawa Y; Onoda N; Kanabuchi K; Abe Y; Nakamura M; Hattori M; Ohno E; Kuramoto H
    Anticancer Res; 2003; 23(1A):115-21. PubMed ID: 12680202
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ADAMTS-6 is a predictor of poor prognosis in patients with esophageal squamous cell carcinoma.
    Liu L; Yang Z; Ni W; Xuan Y
    Exp Mol Pathol; 2018 Apr; 104(2):134-139. PubMed ID: 29475036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of CD44 standard and variant isoforms in parotid gland and parotid gland tumours.
    Franchi A; Moroni M; Paglierani M; Santucci M
    J Oral Pathol Med; 2001 Oct; 30(9):564-8. PubMed ID: 11555161
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression and significance of CD44s, CD44v6, and nm23 mRNA in human cancer.
    Liu YJ; Yan PS; Li J; Jia JF
    World J Gastroenterol; 2005 Nov; 11(42):6601-6. PubMed ID: 16425351
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mitigation of delayed-type hypersensitivity reactions by a CD44 variant isoform v3-specific antibody: blockade of leukocyte egress.
    Seiter S; Engel P; Föhr N; Zöller M
    J Invest Dermatol; 1999 Jul; 113(1):11-21. PubMed ID: 10417612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of microRNA-100 in esophageal squamous cell carcinoma.
    Zhou S; Yang B; Zhao Y; Xu S; Zhang H; Li Z
    J Surg Res; 2014 Dec; 192(2):515-20. PubMed ID: 25218280
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The expression of CFL1 and N-WASP in esophageal squamous cell carcinoma and its correlation with clinicopathological features.
    Wang WS; Zhong HJ; Xiao DW; Huang X; Liao LD; Xie ZF; Xu XE; Shen ZY; Xu LY; Li EM
    Dis Esophagus; 2010 Aug; 23(6):512-21. PubMed ID: 20095995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Establishment of a Novel Anti-CD44 Variant 10 Monoclonal Antibody C
    Ishikawa K; Suzuki H; Kaneko MK; Kato Y
    Curr Issues Mol Biol; 2023 Jun; 45(7):5248-5262. PubMed ID: 37504249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation of CD44S expression in renal clear cell carcinomas with subsequent tumor progression or recurrence.
    Gilcrease MZ; Guzman-Paz M; Niehans G; Cherwitz D; McCarthy JB; Albores-Saavedra J
    Cancer; 1999 Dec; 86(11):2320-6. PubMed ID: 10590373
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overexpression of miR-191 Predicts Poor Prognosis and Promotes Proliferation and Invasion in Esophageal Squamous Cell Carcinoma.
    Gao X; Xie Z; Wang Z; Cheng K; Liang K; Song Z
    Yonsei Med J; 2017 Nov; 58(6):1101-1110. PubMed ID: 29047233
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression and prognostic value of CD44 standard and variant v3 and v6 isoforms in prostate cancer.
    Aaltomaa S; Lipponen P; Ala-Opas M; Kosma VM
    Eur Urol; 2001 Feb; 39(2):138-44. PubMed ID: 11223672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression status of CD44 and CD133 as a prognostic marker in esophageal squamous cell carcinoma treated with neoadjuvant chemotherapy followed by radical esophagectomy.
    Okamoto K; Ninomiya I; Ohbatake Y; Hirose A; Tsukada T; Nakanuma S; Sakai S; Kinoshita J; Makino I; Nakamura K; Hayashi H; Oyama K; Inokuchi M; Nakagawara H; Miyashita T; Hidehiro T; Takamura H; Fushida S; Ohta T
    Oncol Rep; 2016 Dec; 36(6):3333-3342. PubMed ID: 27748881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Expression of CD44 isoforms in normal human liver and also in regenerative and neoplastic liver changes].
    Seelentag WK; Flury R; Schmid M; Komminoth P; Saremaslani P; Günthert U; Heitz PU; Roth J
    Verh Dtsch Ges Pathol; 1995; 79():144-7. PubMed ID: 8600679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss of Protein Tyrosine Phosphatase Receptor J Expression Predicts an Aggressive Clinical Course in Patients with Esophageal Squamous Cell Carcinoma.
    Qiao D; Li M; Pu J; Wang W; Zhu W; Liu H
    Pathol Oncol Res; 2016 Jul; 22(3):541-7. PubMed ID: 26694178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD44v3 and v6 variant isoform expression correlates with poor prognosis in early-stage vulvar cancer.
    Tempfer C; Sliutz G; Haeusler G; Speiser P; Reinthaller A; Breitenecker G; Vavra N; Kainz C
    Br J Cancer; 1998 Oct; 78(8):1091-4. PubMed ID: 9792156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heparan sulfate enhances invasion by human colon carcinoma cell lines through expression of CD44 variant exon 3.
    Kuniyasu H; Oue N; Tsutsumi M; Tahara E; Yasui W
    Clin Cancer Res; 2001 Dec; 7(12):4067-72. PubMed ID: 11751503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD44v3-v10 reduces the profibrotic effects of TGF-β1 and attenuates tubular injury in the early stage of chronic obstructive nephropathy.
    Rampanelli E; Rouschop K; Teske GJ; Claessen N; Leemans JC; Florquin S
    Am J Physiol Renal Physiol; 2013 Nov; 305(10):F1445-54. PubMed ID: 24026183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD44 variant 6 in endometrioid carcinoma of the uterus: its expression in the adenocarcinoma component is an independent prognostic marker.
    Hoshimoto K; Yamauchi N; Takazawa Y; Onda T; Taketani Y; Fukayama M
    Pathol Res Pract; 2003; 199(2):71-7. PubMed ID: 12747468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.